Recordati stock gains as tender offer acceptance climbs toward majority
Published on 09/21/2026 at 20:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Recordati stock (ISIN IT0003828271) is trading firmly as investors react to the progress of a takeover bid for the Italian pharmaceutical group, with the offer’s acceptance level reported at 49.6 percent as of September 21, 2026 according to Teleborsa. The shares changed hands in Milan at EUR 52.37 at 5:35 p.m. local time on September 21, 2026, marking a daily gain of 1.60 percent versus the prior close on Borsa Italiana.
Tender offer drives Recordati stock attention
The current key catalyst for Recordati stock is a cash tender offer aimed at acquiring a controlling stake in the company, with acceptance levels monitored closely by the market. As of September 21, 2026, the participation in the offer stands at 49.6 percent, indicating that nearly half of the free float has already been tendered according to Teleborsa. For shareholders, the acceptance ratio is a central variable, as a move from the current 49.6 percent level toward or beyond a majority threshold would clarify the future ownership structure and the likelihood of a subsequent delisting attempt.
The tender price compared with the latest market quotation offers investors a concrete benchmark to evaluate whether to participate in the offer or to remain exposed to Recordati stock as a listed company. With the shares trading at EUR 52.37 on September 21, 2026 in Milan and recording a 1.60 percent daily increase on that date per Teleborsa, the market level is currently close to the economic terms of the offer, which tends to reduce arbitrage opportunities and place more emphasis on fundamental prospects and governance outcomes.
Recent financials underpin valuation
Beyond the corporate event, Recordati’s valuation continues to be shaped by its recent financial performance. In its latest available half-year report for the first six months of 2026, the group generated consolidated revenue in the mid-single-digit to low-double-digit growth range versus the prior-year period, reflecting ongoing expansion in specialty and rare-disease pharmaceuticals as indicated by company information on its investor-relations pages accessed through Recordati. For the half-year reporting period ending in June 2026, operating profit and net income continued to grow compared with the same period of 2025, driven by volume expansion and a favorable product mix in core therapeutic areas according to disclosures summarized on Recordati.
Key profitability metrics also remained robust. In the half-year 2026 period, Recordati maintained an operating margin in the mid-20s percent area, broadly in line with or slightly above the margin level reported for the comparable half-year of 2025, illustrating disciplined cost control and the resilience of its branded prescription portfolio per data available on Recordati. For investors, the combination of a steady margin profile and revenue growth in the latest half-year period provides a fundamental backstop to the tender offer valuation, since it signals that the underlying business is not solely reliant on one-off events.
Analyst views and key risks around the offer
Recent analyst commentary reflects the dual nature of the investment case: an attractive strategic premium embedded in the offer and the long-term prospects of Recordati’s specialty pharma pipeline. Several research houses covering Recordati have reiterated positive ratings in their September 2026 updates, pointing to the stability of cash generation and the potential upside from late-stage assets, as reported in summary overviews on major financial portals that collate broker recommendations published in the days leading up to September 21, 2026. In those notes, the distance between the prevailing share price level around EUR 52.37 and the implied fair-value ranges remains relatively narrow compared with earlier months, highlighting how the offer terms have anchored expectations in a tight band.
However, analysts also stress that the tender offer is not without risks. A scenario in which the acceptance level remains around the current 49.6 percent mark and fails to progress meaningfully could leave Recordati with a complex shareholder base and an uncertain governance outlook, which might weigh on the stock’s liquidity and on its valuation discount relative to peers. Moreover, the group continues to operate in competitive therapeutic markets and faces regulatory and pricing pressures typical for European pharma companies, factors that could affect its revenue growth trajectory and margin resilience beyond the half-year 2026 period if not offset by successful new product launches.
Recordati stock price and trading snapshot
On Borsa Italiana, Recordati stock closed at EUR 52.37 on September 21, 2026, representing a 1.60 percent rise compared with the previous trading day’s close, with the Milan listing serving as the primary reference venue for the shares per price information from Teleborsa. Based on this price level and recent quotations, the company’s market capitalization stands in the multi-billion-euro range as of late September 2026, placing it among the significant mid-to-large-cap players in the European pharmaceuticals segment. For shareholders evaluating the tender, the current market price close to the offer terms, the 49.6 percent acceptance ratio, and the latest half-year revenue and margin trends together form the key numerical checkpoints for decisions on Recordati stock.
Recordati stock at a glance
- Company: Recordati S.p.A.
- ISIN: IT0003828271
- Ticker: REC
- Trading venue: Borsa Italiana
- Price (as of September 21, 2026, 17:35): 52.37 EUR
- Market capitalization: multi-billion EUR (as of September 21, 2026)
- Sector / Industry: Pharmaceuticals
- Index membership: FTSE Italia Mid Cap
